Navigation Links
HeartWare Receives FDA Approval To Enroll Supplemental Patient Cohort In Destination Therapy Trial
Date:8/27/2013

FRAMINGHAM, Mass. and SYDNEY, Aug. 27, 2013 /PRNewswire/ -- HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that the U.S. Food and Drug Administration (FDA) has approved an IDE (Investigational Device Exemption) Supplement that allows HeartWare to commence enrollment in an additional patient cohort for ENDURANCE, the Company's pivotal, Destination Therapy clinical study.

In this supplemental cohort, HeartWare will enroll up to 286 patients receiving the HeartWare® Ventricular Assist System, as well as up to an additional 143 control patients using a randomization scheme consistent with the ENDURANCE protocol.  Patients will be followed for 12 months after implant.  HeartWare intends to incorporate the data from both this new cohort and ENDURANCE into an anticipated Pre-Market Approval (PMA) Application seeking approval of the HeartWare System for the Destination Therapy indication.  

The protocol for this cohort is designed to confirm clinical observations that sites adhering to more regular monitoring and management of patient blood pressure witnessed a notably lower incidence of neurological events.  

Patient enrollment can commence at the 50 centers participating in the ENDURANCE clinical trial, following Institutional Review Board approvals at each of the centers.  

On November 20, 2012, FDA granted approval of the HeartWare System for the Bridge-to-Transplant indication.  Concurrent with approval, the Company commenced a post-approval study (PAS) to assess device performance in a real-world setting.  HeartWare's PAS is a registry consisting of 600 patients who receive
'/>"/>

SOURCE HeartWare International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. HeartWare Presentation At The Canaccord Genuity 2013 Annual Growth Conference To Be Webcast
2. HeartWare Receives Conditional Approval From FDA to Enroll Supplemental Patient Cohort in Destination Therapy Trial
3. HeartWare Presentation at the Wells Fargo Securities 2013 Healthcare Conference to be Webcast
4. HeartWare International Announces Intention To Delist From Australian Securities Exchange (ASX)
5. HeartWare Presentation At The Goldman Sachs 34th Annual Global Healthcare Conference To Be Webcast
6. HeartWare Presentation At The 2013 UBS Global Healthcare Conference To Be Webcast
7. HeartWare Presentation at the Bank of America Merrill Lynch 2013 Health Care Conference to be Webcast
8. HeartWare International Reports $49.2 Million In First Quarter 2013 Revenue; 87% Increase From First Quarter Of 2012
9. HeartWare Schedules First Quarter Conference Call And Webcast
10. HeartWare International, Inc. Announces Pricing of Public Offering of Common Stock
11. HeartWare International, Inc. Announces Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), ... as a non-invasive, wireless continuous glucose monitoring system, today ... and Interim CEO of Echo Therapeutics, will present at ... Mr. Doman will make a corporate ...
(Date:1/15/2014)... 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... offer by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ... stock of Solta Medical, Inc. (NASDAQ: SLTM ...
(Date:1/14/2014)... 14, 2014 HeartWare International, Inc . (NASDAQ: ... invasive, miniaturized circulatory support technologies that are revolutionizing the ... expects revenues for the fourth quarter of 2013 will ... to approximately $208 million. "Our full-year revenue ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... Calif., April 28, 2011 ... unaudited)ItemQ1 2011Q1 2010 ComparisonTotal BioMarin Revenue , $109.5 , ... increaseNaglazyme Net Product Revenue , $60.6 , 24.7% increaseAldurazyme ... Product Revenue , $26.7 , 25.9% increaseFirdapse Net Product ...
... PDI, Inc. (Nasdaq: PDII ) today announced that ... Tuesday, May 3, 2011 after the market close and host ... Eastern time to discuss the results.Access information:Date: , Wednesday, May ... 644-4654 (U.S. and Canada) or (706) 643-1203 Conference ID number: ...
Cached Medicine Technology:BioMarin Announces First Quarter 2011 Financial Results 2BioMarin Announces First Quarter 2011 Financial Results 3BioMarin Announces First Quarter 2011 Financial Results 4BioMarin Announces First Quarter 2011 Financial Results 5BioMarin Announces First Quarter 2011 Financial Results 6BioMarin Announces First Quarter 2011 Financial Results 7BioMarin Announces First Quarter 2011 Financial Results 8BioMarin Announces First Quarter 2011 Financial Results 9BioMarin Announces First Quarter 2011 Financial Results 10BioMarin Announces First Quarter 2011 Financial Results 11
(Date:7/9/2014)... type of lung cancer, researchers have uncovered mutations in ... tumors. The new knowledge may expand treatments for patients ... are available or are in clinical trials. , Reporting ... Cancer Genome Atlas (TCGA), including researchers at Washington University ... and other institutions, studied tumors from 230 patients with ...
(Date:7/9/2014)... injection drug users in Russia might contribute to ... study, conducted by researchers from Boston University Schools ... St. Petersburg Pavlov State University, sought to discover ... outcomes of a cohort of HIV-positive people with ... were arrested by police were more likely to ...
(Date:7/9/2014)... been a sharp increase in the number of cancer ... online, interactive service that allows patients to view laboratory ... appointments, and renew prescriptions. , Over a six-year period, ... each year increased five-fold, while the number of total ... a study by Dr. David Gerber , Associate ...
(Date:7/9/2014)... smell of flatulence and have a reputation for being highly ... sulfide is now being being found to offer potential health ... heart attacks and dementia. A new compound (AP39), designed and ... to future therapies, by targeting delivery of very small amounts ... cells. , Scientists in Exeter have already found that ...
(Date:7/9/2014)... Small print and poor printing on prescription labels ... may lead to errors in taking medication, according ... and CNIB (Canadian National Institute for the Blind)., ... Pharmacists Journal , found that labels on prescription ... professionally recommended guidelines for legibility. , By simply ...
Breaking Medicine News(10 mins):Health News:Lung cancer study hints at new treatments 2Health News:BU researchers relate arrests with HIV risk environment 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2
... only soybean oil to provide the highest level of ... clean taste., IOWA CITY, Iowa, Feb. 12 An ... only meets the increasing,consumer demand for low trans fat foods, ... so important to food processors., Asoyia Mid Oleic Ultra ...
... N.J., Feb. 12 TeamStaff, Inc.,(Nasdaq: ... and administrative,staffing services, announced today that it ... division, RS Staffing Services, Inc., to TeamStaff,Government ... Georgia based subsidiary currently provides medical, office,administration ...
... Should be considered along with LDL cholesterol ... 12 (HealthDay News) -- A new study showing ... of cardiac trouble strengthens the case for including ... , "Triglycerides traditionally have been viewed as second-class ...
... the recent announcement by,the United States Food and Drug ... Cosmetic (botulinum toxin type A), customers are,looking for alternatives ... FDA approval in 2002 for the temporary treatment of,moderate ... 18 to 65 years,of age. In its recent communication, ...
... DALLAS, Feb. 12 The Beryl Companies announced ... president of product management,and marketing. In this newly ... at a time when new services are being ... strategies., "Mark is a welcome addition to ...
... Association Join Forces to,Educate, African-Americans on Managing ... Feb. 12 A recent survey,commissioned by the ... among African-Americans, two out of three (61,percent) expressed ... of,five (40 percent) expressed concern about developing Alzheimer,s. ...
Cached Medicine News:Health News:Asoyia Announces New Mid Oleic Ultra Low Lin Soybean Oil 2Health News:TeamStaff Renames Subsidiary to Reflect Expanding Government Services 2Health News:TeamStaff Renames Subsidiary to Reflect Expanding Government Services 3Health News:Triglycerides Linked to Coronary Disease Risk 2Health News:Triglycerides Linked to Coronary Disease Risk 3Health News:Botox Cosmetic Alternatives Are Available: Surgical Procedures Offer Solution for Wrinkles 2Health News:New Survey Shows African-Americans Are Concerned With Heart Health but Unaware of Link to Brain Health 2Health News:New Survey Shows African-Americans Are Concerned With Heart Health but Unaware of Link to Brain Health 3Health News:New Survey Shows African-Americans Are Concerned With Heart Health but Unaware of Link to Brain Health 4
... provides anterior column support for single or ... to L5. The system consists of one ... that are stacked to a desired height, ... Fiber Reinforced Polymer material emulates the biomechanical ...
... Jaguar Lumbar I/F Cage system is a ... separate the mechanical and biologic functions of ... Lumbar I/F Cage provides a device designed ... and uses autologous cancellous bone, the best ...
... transmitted through sorted fiberglass bundles ... transmit it to a user's ... designed for rough, industrial handling ... low cost if they should ...
The original Zeppelin High-Speed Motordrill System has been developed to rapidly cut bone, plastic and metal with utmost precision. 120-150 psi - 90.000 rpm - 90g - autoclavable at <134 C....
Medicine Products: